In light of the tremendous scientific developments in the field of thalassemia and sickle cell disease (SCD) with new drugs and treatments that promise to revolutionize the management of these diseases, TIF and UNITED Onlus, the Italian Federation of Thalassemia, Rare Hemoglobinopathies and Drepanocytosis, join forces and invite you to the »1st PanItalian Associations Meeting on New and Innovative Therapies for Haemoglobinopathies », which will take place in virtual mode on Friday, December 18, 2020, 15:00 – 17:00 CET.
More importantly, this virtual event will feature representatives from the Italian Ministry of Health, the Italian Medicines Agency (AIFA), the Italian Society of Haematology (SITE), Thalassaemia Centres, Italian patient organisations and patients with thalassaemia and SCD, and, of course, distinguished medical experts on haemoglobin disorders, who will discuss and interact on key thematic issues, such as:
- The status quo of thalassemia and SCD in Italy
- The advances in the management and treatment of haemoglobinopathies
- The patient access to innovative drugs and therapies in the EU and Italy
The highlight of the meeting will be a dedicated interactive session entitled »Talking With The Experts », where participants will be able to submit their questions to Professors Maria Domenica Cappellini and Lucia de Franceschi and gain valuable insights and in-depth information on various issues with regard to the new and innovative treatments for thalassaemia and SCD.
Although Italy has been a pioneer in the management of hemoglobinopathies for over 30 years, with particular regard to thalassemia, more intensive efforts are needed today to raise awareness among state decision-making bodies and encourage them to make informed decisions for the benefit of patients eligible for such innovative treatments.
The purpose of the meeting, which will be held in Italian, is to establish a genuine and constructive dialogue at national level, between representatives of patient organizations, healthcare professionals, national health authorities, and other interested parties, on the cardinal issue of timely and equal access of thalassemia and sickle cell disease patients to any existing and future innovative treatment and the ways in which it can be achieved.
Register For Free HERE (IT)
View The Full Meeting Programme HERE (IT)